CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Pneumococcal vaccine GSK2189242A (formulation 1) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00896064
NCT00896064Phase 2Completed
CompareCT.gov

A Study to Evaluate Safety and Immunogenicity of a Booster Dose of Two Formulations of GSK Biologicals' Pneumococcal Candidate Vaccine in Healthy Young Adults

GlaxoSmithKline·interventional·Posted May 11, 2009·Updated Aug 17, 2018

In Brief

A Phase 2 clinical trial evaluating Pneumococcal vaccine GSK2189242A (formulation 1) and Pneumococcal vaccine GSK2189242A (formulation 2) for Infections, Streptococcal. Completed, enrolled 43 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of a booster dose of pneumococcal vaccines (GSK 2189242A) in young adults. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT 00707798)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Streptococcal
CountriesBelgium
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 11, 2009
Enrollment StartMay 18, 2009
Primary CompletionAug 5, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.1 years ago

Interventions

Pneumococcal vaccine GSK2189242A (formulation 1)biological

One dose will be administered intramuscularly at Study Day 0.

Pneumococcal vaccine GSK2189242A (formulation 2)biological

One dose will be administered intramuscularly at Study Day 0.